New CAR t cell therapy targets Hard-to-Treat lung cancer
NCT ID NCT07116057
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new type of immunotherapy for people with a specific kind of advanced lung cancer (FRa-positive NSCLC). Researchers take a patient's own immune cells, engineer them to recognize and attack cancer cells, and deliver them directly into the chest cavity. The main goals are to see if this approach is safe and feasible, with only 10 participants enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MOv19-BBz CAR T cells (engineered immune cells targeting a protein called folate receptor-alpha)
- What this could lead to
- If successful, this could point toward a new treatment option for people with certain lung cancers that have not responded to standard therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 10 participants, so it is primarily testing safety, not effectiveness. The treatment involves chemotherapy and a temporary chest tube, which carry risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Can a pill outperform chemo for a Hard-to-Treat lung cancer mutation?
- Can a new drug shrink Hard-to-Treat tumors?
- Breath test may reveal who benefits from lung cancer immunotherapy
- Targeted radiation and immunotherapy join forces against Hard-to-Treat lung cancer
- Triple-Drug cocktail targets tough lung cancer mutations